@Ceazar_Black $ALLR If the DRP-platform is useful to other cancer forms as well, why not split the company in two seperate. One having the DRP-platform. And the other continue to develop Stenoparib for advanced ovarian cancer. Then the value of the DRP would be more visible imo.
$ALLR with cash (no debts), there is really no urgency. Let the readouts play out. And with more favorable data, the valuation will adjust. If it will be bought out for 2B, 5B or even more, we will see. The most important, if you believe in it, is to hold the shares. ๐ค
Mine are no for sale at $2, nor $20. But $200, well yes ๐
@BioTechCash $ALLR I think the key is to forget about it. And look again in 2027. We are still in an early phase. With skilled management, continuous good readouts, we will get there๐ฐ๐ค
@Ceazar_Black $ALLR time and readouts will correct the valuation. A buyout is likely what will happen. Please don't sell the company too early. Hold on and let the bigpharma PAY๐ค